Acro Biomedical Reports No Revenue and Significant Losses in 2025

Acro Biomedical Co., Ltd. reported significant financial challenges in its recent 10-K filing for the fiscal year ending December 31, 2025. The company recorded no revenue for the year, continuing a trend that began in the second and third quarters of 2022. For the years ended December 31, 2025 and 2024, Acro Biomedical incurred net losses of approximately $101,000 and $42,000, respectively. The absence of sales has raised substantial doubt about the company's ability to continue as a going concern, as it has not generated any revenue since December 31, 2022.

The company's operational performance has been severely impacted by external factors, including the political instability in Hong Kong and the effects of China's COVID-19 restrictions. These conditions have hindered the ability of Acro Biomedical's customers, primarily based in Taiwan and Hong Kong, to sell products in the People's Republic of China. As a result, the company recognized a $480,000 bad debt reserve for uncollectible accounts receivable in 2023, reflecting the financial difficulties faced by its customer base.

Strategically, Acro Biomedical has not made significant advancements in product development or market expansion. The company previously explored the development of a cordyceps-infused chicken feed product but has since ceased these efforts. All sales activities have been conducted by the company's chief executive officer, who is currently its only employee and works part-time. The lack of a dedicated marketing organization and the absence of new product launches have contributed to the company's stagnant growth.

In terms of financial resources, Acro Biomedical reported minimal cash reserves and no accounts receivable as of December 31, 2025. The company has relied on advances from a minority stockholder for funding, but there are no agreements in place to secure future financing. The stock is currently traded on the OTC Market Group’s Expert Market, which limits its liquidity and makes it challenging to raise capital. The company has indicated that it may need to issue equity to attract employees and consultants, but this could lead to significant dilution for existing shareholders.

Looking ahead, Acro Biomedical's management acknowledges the need for substantial funding to implement its business plan, which remains in the preliminary stages. The company faces numerous risks, including the inability to generate revenue, develop a customer base, and comply with regulatory requirements if it seeks to enter new markets. Without a clear path to profitability and operational stability, the outlook for Acro Biomedical remains uncertain.